Six-month results from the REMAIN-1 trial showed that Fractyl Health Inc.’s Revita procedure cut post-GLP-1 weight regain by about 70% compared with a sham procedure in patients who discontinued incretin-based drugs such as semaglutide and tirzepatide after achieving substantial weight loss. Read More
Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging. Read More
En Carta Diagnostics SA's EC Pocket Lyme received FDA breakthrough device designation for its rapid, molecular diagnostic test for the early detection of Borrelia bacteria, which causes Lyme disease. The designation marks a pivotal step for the French startup as it will enable closer interaction with the agency, accelerating its route to market, and getting it to patients sooner. Read More
A Jan. 28 report on Medicare spending on lab tests indicated that spending on many types of tests flattened between 2022 and 2024, but spending on genetic tests rose 20% between 2023 and 2024 to $3.6 billion. While the report does not specifically call out fraud as a driver of spending, the U.S. Department of Justice posted a Jan. 26 press release identifying a case of Medicare gene testing fraud that amounted to $52 million, just one of several recent examples of this kind of fraud. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting.
This transition reflects how innovation across the life sciences is increasingly interconnected. By featuring med-tech coverage within BioWorld, readers gain a more complete perspective of key developments in medical technologies alongside therapeutics all in one place.
The final edition of BioWorld MedTech will publish on Jan. 30, 2026, introducing a more streamlined and comprehensive experience for readers starting on Monday, Feb. 2, 2026.
All existing BioWorld MedTech subscribers will be automatically transitioned to BioWorld Premium, ensuring continued access to med-tech coverage as part of a broader view of research, clinical development and commercialization.
As BioWorld continues its mission to cut through the noise of the life sciences industry with accuracy, clarity and context, this integration ensures readers are well-positioned to track the connections shaping innovation across the global life sciences ecosystem.
Thank you for being part of the BioWorld MedTech community. We invite you to continue following coverage within BioWorld.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arcrev, En, Laborie, Moleculight, Organon, Revbio, Sensible Medical, Symmetry Laser. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: CSD Labs, Nextbiomedical, Spectrum Dynamics. Read More
